BRPI0816278A2 - forma sal - Google Patents
forma salInfo
- Publication number
- BRPI0816278A2 BRPI0816278A2 BRPI0816278A BRPI0816278A BRPI0816278A2 BR PI0816278 A2 BRPI0816278 A2 BR PI0816278A2 BR PI0816278 A BRPI0816278 A BR PI0816278A BR PI0816278 A BRPI0816278 A BR PI0816278A BR PI0816278 A2 BRPI0816278 A2 BR PI0816278A2
- Authority
- BR
- Brazil
- Prior art keywords
- salt form
- salt
- Prior art date
Links
- 150000003839 salts Chemical group 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97003007P | 2007-09-05 | 2007-09-05 | |
| PCT/IB2008/002288 WO2009031011A2 (en) | 2007-09-05 | 2008-08-27 | Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0816278A2 true BRPI0816278A2 (pt) | 2015-09-22 |
Family
ID=40293576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0816278A BRPI0816278A2 (pt) | 2007-09-05 | 2008-08-27 | forma sal |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8193181B2 (enExample) |
| EP (1) | EP2215087B1 (enExample) |
| JP (1) | JP2009084270A (enExample) |
| KR (2) | KR101225233B1 (enExample) |
| CN (1) | CN101861314B (enExample) |
| AR (1) | AR068369A1 (enExample) |
| AU (1) | AU2008294473B2 (enExample) |
| BR (1) | BRPI0816278A2 (enExample) |
| CA (1) | CA2697495C (enExample) |
| ES (1) | ES2452965T3 (enExample) |
| IL (1) | IL203973A (enExample) |
| MX (1) | MX2010002518A (enExample) |
| NZ (1) | NZ583582A (enExample) |
| RU (1) | RU2458925C2 (enExample) |
| TW (1) | TWI371277B (enExample) |
| WO (1) | WO2009031011A2 (enExample) |
| ZA (1) | ZA201002356B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0908772D0 (en) * | 2009-05-21 | 2009-07-01 | Astrazeneca Ab | New salts 756 |
| AU2010250923A1 (en) | 2009-05-21 | 2011-11-17 | Astrazeneca Ab | Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases |
| AU2012253885A1 (en) | 2011-05-10 | 2013-10-31 | Merck Sharp & Dohme Corp. | Aminopyrimidines as Syk inhibitors |
| CA2834062A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as syk inhibitors |
| WO2012154518A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
| US8987456B2 (en) | 2011-10-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
| WO2013052391A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| EP2763976B1 (en) | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| EP2768480A1 (en) * | 2011-10-21 | 2014-08-27 | Rigel Pharmaceuticals, Inc. | Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4]oxazin-3-one) -6-yl]-5-fluoro-n2- [3- (methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine |
| EP2863913B1 (en) | 2012-06-20 | 2018-09-12 | Merck Sharp & Dohme Corp. | Imidazolyl analogs as syk inhibitors |
| WO2013192125A1 (en) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
| US9376418B2 (en) | 2012-06-22 | 2016-06-28 | Merck Sharp & Dohme Corp. | Substituted pyridine spleen tyrosine kinase (SYK) inhibitors |
| WO2013192088A1 (en) | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| EP2884982B1 (en) | 2012-08-20 | 2017-09-20 | Merck Sharp & Dohme Corp. | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| WO2014048065A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
| EP2931281B1 (en) | 2012-12-12 | 2018-01-17 | Merck Sharp & Dohme Corp. | Amino-pyrimidine-containing spleen tyrosine kinase inhibitors |
| EP2934525B1 (en) | 2012-12-21 | 2019-05-08 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors |
| CN105188759A (zh) * | 2013-03-14 | 2015-12-23 | 阿勒根公司 | 持续释放递送的组合物以及在制造过程中稳定蛋白质的方法 |
| EP2988744A4 (en) | 2013-04-26 | 2016-11-02 | Merck Sharp & Dohme | THIAZOLSUBSTITUTED AMINOHETEROARYLE AS MILZTYROSINKINASE INHIBITOR |
| WO2014176216A1 (en) | 2013-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors |
| US9670196B2 (en) | 2013-12-20 | 2017-06-06 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors |
| WO2015094997A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| EP3083559B1 (en) | 2013-12-20 | 2021-03-10 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| WO2015138273A1 (en) | 2014-03-13 | 2015-09-17 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
| WO2018189566A1 (en) * | 2017-04-10 | 2018-10-18 | Dorian Bevec | Use of a chemical compound as a therapeutic agent |
| US11149029B2 (en) * | 2018-07-18 | 2021-10-19 | Astrazeneca Ab | Salts of IJAK inhibitors and methods of using the same |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| GB9808802D0 (en) * | 1998-04-24 | 1998-06-24 | Glaxo Group Ltd | Pharmaceutical formulations |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0208609D0 (en) * | 2002-04-13 | 2002-05-22 | Glaxo Group Ltd | Compositions |
| US20040138200A1 (en) * | 2002-10-04 | 2004-07-15 | Michael Hawley | Pharmaceutical compositions for treatment of Parkinson's disease |
| ES2421139T3 (es) * | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| KR20080024532A (ko) * | 2005-06-15 | 2008-03-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 신규한 티오트로퓸 염의 제조방법, 신규한 티오트로퓸 염및 이의 약제학적 조성물 |
| US8198450B2 (en) * | 2006-06-30 | 2012-06-12 | Novartis Ag | Quinolinone derivatives and their pharmaceutical compositions |
-
2008
- 2008-08-27 ES ES08806983.6T patent/ES2452965T3/es active Active
- 2008-08-27 WO PCT/IB2008/002288 patent/WO2009031011A2/en not_active Ceased
- 2008-08-27 US US12/676,075 patent/US8193181B2/en not_active Expired - Fee Related
- 2008-08-27 NZ NZ583582A patent/NZ583582A/en not_active IP Right Cessation
- 2008-08-27 AU AU2008294473A patent/AU2008294473B2/en not_active Ceased
- 2008-08-27 RU RU2010108162/04A patent/RU2458925C2/ru active
- 2008-08-27 CN CN200880105757XA patent/CN101861314B/zh not_active Expired - Fee Related
- 2008-08-27 CA CA2697495A patent/CA2697495C/en not_active Expired - Fee Related
- 2008-08-27 KR KR1020107007283A patent/KR101225233B1/ko not_active Expired - Fee Related
- 2008-08-27 KR KR1020127024371A patent/KR20120120453A/ko not_active Withdrawn
- 2008-08-27 EP EP08806983.6A patent/EP2215087B1/en not_active Not-in-force
- 2008-08-27 BR BRPI0816278A patent/BRPI0816278A2/pt not_active Application Discontinuation
- 2008-08-27 MX MX2010002518A patent/MX2010002518A/es active IP Right Grant
- 2008-09-03 JP JP2008225403A patent/JP2009084270A/ja active Pending
- 2008-09-04 AR ARP080103848A patent/AR068369A1/es unknown
- 2008-09-04 TW TW097133970A patent/TWI371277B/zh not_active IP Right Cessation
-
2010
- 2010-02-15 IL IL203973A patent/IL203973A/en active IP Right Grant
- 2010-04-01 ZA ZA2010/02356A patent/ZA201002356B/en unknown
-
2012
- 2012-05-09 US US13/467,850 patent/US8486935B2/en not_active Expired - Fee Related
-
2013
- 2013-06-18 US US13/920,434 patent/US20130281446A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101861314A (zh) | 2010-10-13 |
| KR20120120453A (ko) | 2012-11-01 |
| US20100204232A1 (en) | 2010-08-12 |
| RU2010108162A (ru) | 2011-09-10 |
| RU2458925C2 (ru) | 2012-08-20 |
| AU2008294473A1 (en) | 2009-03-12 |
| HK1144685A1 (en) | 2011-03-04 |
| CN101861314B (zh) | 2013-07-24 |
| WO2009031011A2 (en) | 2009-03-12 |
| EP2215087B1 (en) | 2013-12-18 |
| NZ583582A (en) | 2012-02-24 |
| EP2215087A2 (en) | 2010-08-11 |
| AR068369A1 (es) | 2009-11-11 |
| JP2009084270A (ja) | 2009-04-23 |
| ZA201002356B (en) | 2010-12-29 |
| WO2009031011A3 (en) | 2009-04-30 |
| KR20100049688A (ko) | 2010-05-12 |
| ES2452965T3 (es) | 2014-04-03 |
| US8486935B2 (en) | 2013-07-16 |
| AU2008294473B2 (en) | 2013-12-05 |
| US20130281446A1 (en) | 2013-10-24 |
| CA2697495A1 (en) | 2009-03-12 |
| US20120316160A1 (en) | 2012-12-13 |
| TW200927125A (en) | 2009-07-01 |
| IL203973A (en) | 2013-10-31 |
| TWI371277B (en) | 2012-09-01 |
| MX2010002518A (es) | 2010-03-26 |
| KR101225233B1 (ko) | 2013-01-22 |
| US8193181B2 (en) | 2012-06-05 |
| CA2697495C (en) | 2013-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0807004A2 (pt) | Sal | |
| BRPI0813500A2 (pt) | Compostos antivirais | |
| BRPI0821086A2 (pt) | Compostos inseticidas | |
| ATE501136T1 (de) | Imidazopyridinone | |
| BRPI0807137A2 (pt) | Agentes antiparasitários | |
| DK2178568T3 (da) | Kontrastmidler | |
| DK2132326T3 (da) | Fremgangsmåder | |
| BRPI0811264A2 (pt) | Compostos | |
| FI20075851A0 (fi) | Muodostusosa | |
| FI20086008A0 (fi) | Muodostusosa | |
| BRPI0809996A2 (pt) | Compostos | |
| BRPI0814424A2 (pt) | Compostos heterociclila | |
| AT505058A3 (de) | Türschliesssystem | |
| BRPI0809678A2 (pt) | Métodos | |
| BRPI0815181A2 (pt) | Compostos | |
| BRPI0807882A2 (pt) | Forma de dosagem | |
| BRPI0814613A2 (pt) | Compostos | |
| LT3825306T (lt) | Morfinano junginiai | |
| FI20065446A0 (fi) | Muodostusosa | |
| IT1398018B1 (it) | Obice rimorchiato | |
| BRPI0812223A2 (pt) | Realce do sal | |
| BRPI0917978A2 (pt) | sal de 2-hidróxi-etanossulfonato | |
| ES1065818Y (es) | Picaporte magnetico | |
| FI20086007A0 (fi) | Muodostusosa | |
| AT9563U3 (de) | Wirbelsäulenzuggurtung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: RIGEL PHARMACEUTICALS, INC. (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |